REVIEW ARTICLE
Year : 2022 | Volume
: 13 | Issue : 4 | Page : 167--171
Anticoagulant status under COVID-19: The potential pathophysiological mechanism
Basheer Abdullah Marzoog
Medical School Student at National Research Mordovia State University, Saransk, Russia
Correspondence Address:
Dr. Basheer Abdullah Marzoog
Mordovia Republic, Saransk, Bolshevitskaya Street, 31
Russia
Coronavirus disease 19 (COVID-19) is a systematic multitropic disease. Sustaining blood homeostasis is a mission of multiple factors includes procoagulant and anticoagulant systems. Subsequently, maintaining a precise equilibrium between these antagonists' systems is crucial to prevent hemostasis. Frequently, during severe forms of COVID-19 patients, studies reported a discrepancy between the procoagulant and anticoagulant that usually results in fatal outcomes through multiorgan ischemia by thrombotic events. The proper interpreting of the anticoagulant status changes in COVID-19 patients is sufficient for effective and safe anticoagulant treatment. Our postulation is the first to address the pathophysiology of anticoagulant status under COVID-19.
How to cite this article:
Marzoog BA. Anticoagulant status under COVID-19: The potential pathophysiological mechanism.J Appl Hematol 2022;13:167-171
|
How to cite this URL:
Marzoog BA. Anticoagulant status under COVID-19: The potential pathophysiological mechanism. J Appl Hematol [serial online] 2022 [cited 2023 Sep 22 ];13:167-171
Available from: https://www.jahjournal.org/article.asp?issn=1658-5127;year=2022;volume=13;issue=4;spage=167;epage=171;aulast=Marzoog;type=0 |
|
